Phase 2 Clinical Trial Evaluating the Safety, Tolerability, and Effectiveness of Venetoclax combined with Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Verified

What's the purpose of this trial?

The goal of this clinical trial is to determine the safety, effectiveness, and tolerability of venetoclax in combination with carfilzomib and dexamethasone. This combination is being evaluated in participants with relapsed/refractory multiple myeloma. 

This trial is currently open and accepting patients.


What will happen during the trial?

This trial is organized into four parts, with only part 4 currently enrolling. Part 4 of this clinical trial is organized into three different groups, or arms. Participants will be randomly assigned into one of the three arms. This trial is open- label, which means that both researchers and trial participants will know which arm they are placed in, and which study treatments they will be receiving. Each arm is organized into 28 day cycles, and participants may continue to receive the study treatments as long as they don’t develop bad side effects and their myeloma doesn’t get worse. 

Arm A: Participants in this arm will receive Venetoclax, Carfilzomib, and Dexamethasone. Venetoclax will be given by mouth, every day, at a lesser dose than Arm B will receive. Carfilzomib will be given by intravenous infusion weekly during the first three weeks of each cycle. Dexamethasone will be given either by mouth or by intravenous infusion weekly (cycles 1-9), and then weekly for the first three weeks of each cycle (cycles 10 and onwards). 

Arm B: Participants in this arm will receive Venetoclax, Carfilzomib, and Dexamethasone. Venetoclax will be given by mouth, every day, at a higher dose than Arm A will receive. Carfilzomib will be given by intravenous infusion weekly during the first three weeks of each cycle. Dexamethasone will be given either by mouth or by intravenous infusion weekly (cycles 1-9), and then weekly for the first three weeks of each cycle (cycles 10 and onwards). 

Arm C: Participants in this arm will receive Carfilzomib by intravenous infusion weekly during the first three weeks of each cycle. They will also receive Dexamethasone either by mouth or by intravenous infusion weekly (cycles 1-9), and then weekly for the first three weeks of each cycle (cycles 10 and onwards).

There may be an opportunity for participants to be reimbursed for some of their travel expenses for study related visits. Once a participant has established care at one of the study sites, the staff will share the details of potential reimbursement.

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

You may be able to join this trial if you:

  • have a diagnosis of relapsed/refractory multiple myeloma, and your myeloma has tested positive for translocation 11;14. 
  • have received at least one prior line of therapy for your multiple myeloma.
  • have not previously received carfilzomib.
  • have not previously received venetoclax or another BCL-2 inhibitor.
  • have not had an allogeneic stem cell transplant in the previous six months, and have not had an autologous transplant in the previous three months. 

Additional Trial Information

Phase 2

Enrollment: 120 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

Alabama

UAB Comprehensive Cancer Center University of Alabama at Birmingham

Birmingham, AL

Open and Accepting

Arkansas

University of Arkansas for Medical Sciences (UAMS)

Little Rock, AR

Open and Accepting

California

Marin Cancer Care

Greenbrae, CA

Not Yet Accepting

Florida

Memorial Cancer Institute Memorial Regional Hospital

Hollywood, FL

Open and Accepting

Georgia

Winship Cancer Institute of Emory University

Atlanta, GA

Open and Accepting

Indiana

Blood and Marrow Transplantation Franciscan Health

Indianapolis, IN

Open and Accepting

Maine

Central Maine Medical Center

Lewiston, ME

Open and Accepting

Missouri

Alvin J. Siteman Cancer Center Washington University Medical Campus

St. Louis, MO

Open and Accepting

Oncology Hematology Associates (OHA)

Springfield, MO

Open and Accepting

North Carolina

Carolinas Medical Center

Charlotte, NC

Not Yet Accepting

Duke Cancer Center Duke University Medical Center

Durham, NC

Open and Accepting

Pennsylvania

Abramson Cancer Center University of Pennsylvania

Philadelphia, PA

Open and Accepting

Texas

Baylor Scott & White Hospital

Temple, TX

Open and Accepting

Utah

Huntsman Cancer Institute University of Utah

Salt Lake City, UT

Open and Accepting

Wisconsin

Aurora Research Institute

Wauwatosa, WI

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

SparkCures is working closely with AbbVie to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors